Allos Therapeutics Announces Closing of Common Stock Offering
April 03 2009 - 3:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH) announced today the
closing of its previously reported underwritten public offering of
7,750,000 shares of its common stock at the public offering price
of $6.30 per share. The Company received net proceeds from the
offering of approximately $46.8 million, after deducting
underwriting commissions and estimated offering expenses. The
Company plans to use the net proceeds from the offering primarily
for activities relating to preparations for the potential
commercial launch of pralatrexate, clinical and preclinical
research and development of pralatrexate, working capital and
general corporate purposes.
UBS Investment Bank was the sole manager for the offering. The
Company has granted the underwriter a 30-day option to purchase up
to an additional 1,162,500 shares to cover over-allotments, if any.
Copies of the prospectus supplement relating to this offering may
be obtained from UBS Investment Bank, Attention: Prospectus
Department, 299 Park Avenue, New York, NY 10171, or by calling
(888) 827-7275.
A registration statement relating to these shares was filed with
the Securities and Exchange Commission and declared effective on
June 5, 2007. This press release does not and shall not constitute
an offer to sell or the solicitation of an offer to buy the
Company's common stock, nor shall there be any sale of the common
stock in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the amount of the net
proceeds, the potential to complete the Company�s ongoing
development programs with the proceeds of the financing, and other
statements which are other than statements of historical facts. In
some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends,"
"plans," anticipates," "believes," "estimates," "predicts,"
"projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean
that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others: the risk that additional capital may be required in
the future for the potential commercial launch of pralatrexate and
to complete on-going trials. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2008, the
Company's other periodic reports and filings with the SEC and the
prospectus supplement related to the offering. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Oct 2023 to Oct 2024